VAERS Explorer
Back to explore

Report #2897756

Received May 25, 2026

Life-threatening
A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
Recovered
Unknown
Vaccinated
Onset
Days to onset
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS1UNK

Symptoms (1)

Near death experience

Symptom narrative

the first vaccine almost killed him; This serious case was reported by a consumer via interactive digital media and described the occurrence of near death experience in a male patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced near death experience (Verbatim: the first vaccine almost killed him) (serious criteria GSK medically significant and life threatening). Shingrix was discontinued. The outcome of the near death experience was unknown. The reporter considered the near death experience to be related to Shingrix. The company considered the near death experience to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 06-MAY-2026 This case was reported by a patient via interactive digital media. The patient mentioned that first shot almost killed him and he said that not taking the second dose of Shingrix. The batch number was not provided and unable to contact the reporter.; Sender's Comments: A case of Near death experience, unknown time after receiving 1st dose of Shingrix in a male patient. Case lacks further information on time to onset, medical history, concurrent conditions and laboratory data. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.